Anika Therapeutics Inc   (ANIK)
Other Ticker:  
Price: $18.8300 $0.14 0.749%
Day's High: $18.95 Week Perf: -1.77 %
Day's Low: $ 18.43 30 Day Perf: 4.5 %
Volume (M): 91 52 Wk High: $ 32.51
Volume (M$): $ 1,704 52 Wk Avg: $26.37
Open: $18.63 52 Wk Low: $16.54

 Market Capitalization (Millions $) 277
 Shares Outstanding (Millions) 15
 Employees 187
 Revenues (TTM) (Millions $) 162
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Anika Therapeutics Inc
Anika Therapeutics Inc is a global medical technology company that specializes in tissue-medical devices for the regenerative treatment of pain and musculoskeletal conditions. The company is headquartered in Bedford, Massachusetts, USA, and operates in over 30 countries worldwide.

Anika Therapeutics Inc was founded in 1992 by Charles H. Sherwood, Ph.D., and Richard G. Steadman, M.D, with a vision to create and deliver products that could help to promote the healing and recovery of individuals suffering from musculoskeletal injuries or diseases. The company has since grown to become a leading provider of advanced medical devices and therapies, using a range of technologies developed in-house.

The company's core product offering includes a number of tissue implants, including Orthovisc, Monovisc, and Cingal, which are designed to help alleviate the pain and mobility issues experienced by patients with osteoarthritis. These devices, which are made using high-purity hyaluronic acid, are injected into the joint to lubricate and cushion the affected area, providing long-lasting relief.

In addition to these products, Anika Therapeutics Inc also offers a range of other medical devices and solutions, such as the AmnioExcel amniotic membrane product, which is used in wound healing, and the Hyalofast scaffold, which allows for the delivery of cells and growth factors in tissue engineering repair applications.

Anika Therapeutics Inc is proud of its commitment to quality and innovation, investing heavily in research and product development to improve the efficacy and range of its medical solutions. The company has a strong record of innovation, having filed over 100 patents to date, and regularly collaborates with leading medical institutions and industry partners to develop and improve its products.

Overall, Anika Therapeutics Inc offers a diverse range of innovative, high-quality medical solutions designed to address a range of musculoskeletal concerns, improving patient outcomes and quality of life. Its focus on quality, innovation, and collaboration has helped establish it as a leader in the industry, and it continues to grow and expand its product offerings to address the evolving needs of patients worldwide.

   Company Address: 32 Wiggins Avenue Bedford 1730 MA
   Company Phone Number: 457-9000   Stock Exchange / Ticker: NASDAQ ANIK
   ANIK is expected to report next financial results on November 08, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Fonar Corporation

Fonar Corporation Faces Steep Decline in Fourth Quarter, Sinking into Negative Territory

In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment and Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery.
Financial Performance
Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment and Supplies sector as a whole.

Precision Optics Corporation Inc

Precision Optics Corporation Inc Announces a Remarkable Financial Turnaround, Amidst Challenging Market Conditions, in Q4 2023 Financial Report

Precision Optics Corporation Inc (POCI) has experienced a slight increase in its stock value over the past week, rising by 0.66%. Additionally, its stock currently trades 6.5% above its 52-week low. These figures indicate positive performance for the company in the stock market.
Examining POCI's financial report for the fourth quarter of 2023, it is evident that the company faced a net loss per share of $-0.11. This represents a decline from the $0.08 per share profit reported in the previous year. However, despite the loss, POCI saw a 4.811% increase in revenue, reaching $5.02 million compared to the corresponding reporting period the previous year.

Heart Test Laboratories Inc

Advanced Heart Test Laboratories Inc. Witnesses Promising Revenue Similar to Previous Year's Quarter, as Efforts Focus on Q1 2024

Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.

Sensasure Technologies Inc

Company Struggles Amidst Challenging First Quarter in 2024

Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.

Innovage Holding Corp

Innovage Holdings Corp Suffers Loss Despite Revenue Surge in Fourth Quarter of 2023

Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.


Anika Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com